9 completed, 2 terminated. 8 Phase 2, 4 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Terminated 2 |
| Phase 1 | 4 | Completed 4 |
| Not applicable | 1 | Completed 1 |
Follow Parion Sciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device tPAD Device, PARI LC Star Nebulizer - Lung Diseases | Not applicable | Completed | University of North Carolina, Chapel Hill | 12 | 2017-07-27 | 2018-10-03 |
| Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia VX-371, Hypertonic Saline, Placebo (0.17% saline) - Primary Ciliary Dyskinesia | Phase 2 | Completed | Parion Sciences | 123 | 2016-08-01 | 2021-12-16 |
| Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo - Dry Eye Disease | Phase 2 | Terminated | Parion Sciences | 47 | 2016-07-01 | 2018-10-11 |
| Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo - Dry Eye Disease | Phase 2 | Terminated | Parion Sciences | 1 | 2016-07-01 | 2018-08-31 |
| A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation VX-371 + HS, Hypertonic saline, Placebo - Cystic Fibrosis | Phase 2 | Completed | Parion Sciences | 147 | 2016-02-01 | 2021-07-29 |
| Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF) P-1037, Hypertonic Saline, Saline - Cystic Fibrosis | Phase 2 | Completed | Parion Sciences | 142 | 2015-04-01 | 2021-07-26 |
| Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo - Dry Eye Disease | Phase 1 | Completed | Parion Sciences | 53 | 2014-07-01 | 2015-05-04 |
| A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device inhaled hypertonic saline (7%) - Cystic Fibrosis | Phase 1 | Completed | University of Pittsburgh | 12 | 2014-06-01 | 2017-07-25 |
| An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness P-552, Placebo - Xerostomia, Sjogren's Syndrome | Phase 1 / Phase 2 | Completed | Parion Sciences | 24 | 2010-11-01 | 2019-04-23 |
| A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome Placebo, 552-02 - Dry Mouth Associated With Sjogren's Syndrome, Xerostomia | Phase 2 | Completed | Parion Sciences | 140 | 2009-02-01 | 2018-09-18 |
| Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients 552-02 - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Parion Sciences | 40 | 2006-01-01 | 2009-01-14 |
Cystic Fibrosis (4) · Dry Eye Syndromes (3) · Sjogren's Syndrome (2) · Xerostomia (2) · Ciliary Motility Disorders (1) · Lung Diseases (1)
Saline Solution, Hypertonic (3) · Sodium Chloride (3) · Hydrogen-Ion Concentration (1) · Injections (1) · Water (1) · ivacaftor (1) · lumacaftor, ivacaftor drug combination (1)
United States (11) · United Kingdom (2) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · Netherlands (1) · Poland (1)
Jose Boyer (2) · Karl Donn (2) · Alison Church, MD (1) · Joseph M Pilewski, MD (1) · Kenneth Sall, MD (1) · Scott Donaldson, MD (1)
2015 (2)